TGFB1 and Hepatic fibrosis: In liver fibrosis models, Liu et al. (2009a,b) reported that vatalanib attenuated stellate cell activation and liver fibrosis progression by inhibiting VEGF signaling as well as targeting of the PDGF and TGF-β-signaling pathways.